查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1600269

结核病检测市场：按检测项目、适应症、检测地点和最终用户划分 - 全球预测 2025-2030

Tuberculosis Testing Market by Test (Culture-Based Tests, Interferon-Gamma Release Assays, Mantoux Tuberculin Skin Test), Indication (Active TB Infection, Latent TB Infection), Testing Location, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年结核病检测市场价值为22.5亿美元，预计到2024年将达到23.8亿美元，复合年增长率为5.88%，到2030年将达到33.6亿美元。

结核病检测市场包括用于检测结核病感染的各种诊断测试，例如皮肤测试、血液检查、显微镜检查、核酸测试和基于培养的测试。这些检测对于识别活动性结核病病例和潜伏性结核病感染至关重要，有助于限制这种传染病的传播。结核病检测的必要性在于其在流行区域和非流行区的应用，以遏制传播并提供有针对性的治疗。结核病检测在医院、诊所和诊断实验室等医疗机构中至关重要，有助于卫生署和政府改善公共卫生的努力。该市场的驱动因素包括发病率的增加、对早期准确诊断的需求不断增长以及测试准确性和速度的进步。该领域最新的潜在商机之一来自数位健康技术和人工智慧测试解释的集成，这可能会导致更快的诊断和改进的患者管理。市场成长受到政府努力根除结核病、提高意识和筛检计画以及增加研发资金等因素的影响。限制包括特别先进的分子测试的高成本、资源匮乏环境中的基础设施挑战以及对熟练人员的需求。挑战包括结核病感染的隐藏性，这使得及时诊断和公共卫生应对变得复杂。最佳的创新领域是开发更容易获得且更具成本效益的就地检验，这些测试可以在偏远和服务不足的地区进行。这包括快速检测套组和移动测试装置等。疫苗开发研究也是创新的沃土。该市场正在适应公共卫生机构和私人公司之间日益加强的伙伴关係关係，以加强检测基础设施和推广计划，使其成为一个充满机会和挑战的充满活力的领域。

主要市场统计
基准年[2023] 22.5亿美元
预测年份 [2024] 23.8亿美元
预测年份 [2030] 33.6亿美元
复合年增长率（%） 5.88%

市场动态：揭示快速发展的结核病检测市场的关键市场洞察

供需的动态交互作用正在改变结核病检测市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球结核病患率上升
    • 政府和监管机构提高对结核病的认识和控制计划
    • 照护现场高机率结核病检测
  • 市场限制因素
    • 高阶结核病检测成本高昂
  • 市场机会
    • 不断发展诊断技术以实现更快的诊断
    • 增加配备先进设备的结核病诊断中心数量
  • 市场挑战
    • 擅长管理和解释结核病检测的医疗保健专业人员

波特五力：开拓结核病检测市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解结核病检测市场的外部影响

外部宏观环境因素在塑造结核病检测市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解结核病检测市场的竞争格局

对结核病检测市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵结核病检测市场供应商的绩效评估

FPNV定位矩阵是评估结核病检测市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划结核病检测市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，结核病检测市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告提供了涵盖关键重点领域的市场全面分析：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地的结核病发病率正在上升
      • 政府和监管机构扩大结核病认识和控制计划
      • 照护现场高机率结核病检测
    • 抑制因素
      • 高阶结核病检测高成本
    • 机会
      • 不断发展诊断技术以实现更快的诊断
      • 增加配备先进设备的结核病诊断中心
    • 任务
      • 熟悉执行和解释结核病检测的熟练医疗保健专业人员
  • 市场区隔分析
    • 检验：非侵入性和有效性正在增加 IGRA 在诊断潜伏性结核感染的使用
    • 最终用户：透过政府和公共卫生机构轻鬆进行结核病检测，以减少结核病的传播并实现公共卫生目标。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 结核病检测市场（依检测）

  • 基于文化的测试
  • 干扰素-γ释放测定
  • Mantot结核菌素皮肤试
  • 核酸增幅检查
  • 涂片显微镜检查

第七章 结核病检测市场（依适应症）

  • 活动性结核感染疾病
  • 潜伏性结核感染

第八章依检测地点分類的结核病检测市场

  • 实验室测试
  • 就地检验

第九章结核病检测市场：依最终用户分类

  • 诊断实验室
  • 政府和公共卫生机构
  • 医院
  • 研究/学术机构

第十章美洲结核病检测市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太结核病检测市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲结核病检测市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争场景分析
    • Revvity 推出先进的结核病检测自动化技术，提高效率和准确性
    • MedGenome 与 Darshan GIVA 基金会合作，透过全基因组定序增强结核病诊断
    • VinBrain 与越南国家结核病筛检倡议合作根除结核病
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Becton, Dickinson, and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Bruker Corporation
  • Cepheid by Danaher Corporation
  • Elisabeth Pharmacon, spol. s ro
  • ELITech Group SAS
  • F. Hoffmann-La Roche AG
  • Fujifilm Holdings Corporation
  • Hologic Corporation
  • Lionex Diagnostics & Therapeutics GmbH
  • OSANG HEALTHCARE CO., LTD
  • PerkinElmer, Inc.
  • SD Biosensor, INC.
  • Siemens AG
  • Thermo Fisher Scientific, Inc.
  • Trivitron Healthcare Private Limited
  • Tulip Diagnostics（P）Ltd
  • Turklab AS
Product Code: MRR-03252A5F927A

The Tuberculosis Testing Market was valued at USD 2.25 billion in 2023, expected to reach USD 2.38 billion in 2024, and is projected to grow at a CAGR of 5.88%, to USD 3.36 billion by 2030.

The scope of the Tuberculosis (TB) Testing market encompasses various diagnostic tests used to detect TB infections, including skin tests, blood tests, microscopy, nucleic acid tests, and culture-based tests. These tests are crucial in identifying active TB cases and latent TB infections, which aids in controlling the spread of this contagious disease. The necessity of TB testing lies in its application in both endemic and non-endemic regions to curb transmission and provide targeted treatment. They are essential in healthcare settings such as hospitals, clinics, and diagnostic laboratories, serving health departments and governments aiming for public health advancement. The market is driven by increasing incidence rates, a rising need for early and precise diagnostics, and advancements in test accuracy and speed. One of the latest potential opportunities within this sector arises from the integration of digital health technologies and AI for test interpretation, which can lead to quicker diagnosis and improved patient management. Market growth is influenced by factors such as government initiatives for TB eradication, rising awareness and screening programs, and increasing funding for R&D. Limitations include high costs, especially for advanced molecular tests, infrastructural challenges in low-resource settings, and the requirement for skilled personnel. A challenging factor is the latent nature of TB infections, which complicates timely diagnosis and public health responses. The best areas for innovation touch upon developing more accessible, cost-effective point-of-care tests that can be implemented in remote or underserved areas. This could include simplified test kits or mobile testing units. Research into vaccine development also represents a fertile ground for innovation. The market is adapting with an increase in partnerships between public health bodies and private enterprises to enhance testing infrastructure and outreach programs, making it a dynamic field ripe with both opportunities and challenges.

KEY MARKET STATISTICS
Base Year [2023] USD 2.25 billion
Estimated Year [2024] USD 2.38 billion
Forecast Year [2030] USD 3.36 billion
CAGR (%) 5.88%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Tuberculosis Testing Market

The Tuberculosis Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rise in the prevalence of tuberculosis worldwide
    • Growing tuberculosis awareness and control programs by government and regulatory authorities
    • High potential of point-of-care tuberculosis testing
  • Market Restraints
    • High cost of advanced tuberculosis testings
  • Market Opportunities
    • Ongoing developments in diagnostic technologies that enable faster diagnosis
    • Increasing number of tuberculosis diagnostic centers with advanced facilities
  • Market Challenges
    • Skilled healthcare professionals proficient in administering and interpreting TB tests

Porter's Five Forces: A Strategic Tool for Navigating the Tuberculosis Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Tuberculosis Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Tuberculosis Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Tuberculosis Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Tuberculosis Testing Market

A detailed market share analysis in the Tuberculosis Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Tuberculosis Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Tuberculosis Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Tuberculosis Testing Market

A strategic analysis of the Tuberculosis Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Tuberculosis Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Becton, Dickinson, and Company, Bio-Rad Laboratories, Inc., bioMerieux SA, Bruker Corporation, Cepheid by Danaher Corporation, Elisabeth Pharmacon, spol. s r.o., ELITech Group SAS, F. Hoffmann-La Roche AG, Fujifilm Holdings Corporation, Hologic Corporation, Lionex Diagnostics & Therapeutics GmbH, OSANG HEALTHCARE CO., LTD, PerkinElmer, Inc., SD Biosensor, INC., Siemens AG, Thermo Fisher Scientific, Inc., Trivitron Healthcare Private Limited, Tulip Diagnostics (P) Ltd, and Turklab A.S..

Market Segmentation & Coverage

This research report categorizes the Tuberculosis Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Test, market is studied across Culture-Based Tests, Interferon-Gamma Release Assays, Mantoux Tuberculin Skin Test, Nucleic Acid Amplification Tests, and Smear Microscopy.
  • Based on Indication, market is studied across Active TB Infection and Latent TB Infection.
  • Based on Testing Location, market is studied across In-laboratory Testing and Point-of-Care Testing.
  • Based on End User, market is studied across Diagnostic Laboratories, Government & Public Health Organizations, Hospital, and Research & Academic Institutions.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in the prevalence of tuberculosis worldwide
      • 5.1.1.2. Growing tuberculosis awareness and control programs by government and regulatory authorities
      • 5.1.1.3. High potential of point-of-care tuberculosis testing
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of advanced tuberculosis testings
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing developments in diagnostic technologies that enable faster diagnosis
      • 5.1.3.2. Increasing number of tuberculosis diagnostic centers with advanced facilities
    • 5.1.4. Challenges
      • 5.1.4.1. Skilled healthcare professionals proficient in administering and interpreting TB tests
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Test: Growing usage of IGRA in diagnosing latent TB infection due to their non-invasive nature and effectiveness
    • 5.2.2. End User: High accessibility to tuberculosis testing through government and public health organizations to curb the spread of TB and achieve public health goals
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Tuberculosis Testing Market, by Test

  • 6.1. Introduction
  • 6.2. Culture-Based Tests
  • 6.3. Interferon-Gamma Release Assays
  • 6.4. Mantoux Tuberculin Skin Test
  • 6.5. Nucleic Acid Amplification Tests
  • 6.6. Smear Microscopy

7. Tuberculosis Testing Market, by Indication

  • 7.1. Introduction
  • 7.2. Active TB Infection
  • 7.3. Latent TB Infection

8. Tuberculosis Testing Market, by Testing Location

  • 8.1. Introduction
  • 8.2. In-laboratory Testing
  • 8.3. Point-of-Care Testing

9. Tuberculosis Testing Market, by End User

  • 9.1. Introduction
  • 9.2. Diagnostic Laboratories
  • 9.3. Government & Public Health Organizations
  • 9.4. Hospital
  • 9.5. Research & Academic Institutions

10. Americas Tuberculosis Testing Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Tuberculosis Testing Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Tuberculosis Testing Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Revvity Introduces Advanced Automation for Tuberculosis Testing, Enhancing Efficiency and Accuracy
    • 13.3.2. MedGenome Collaborates with Darshan GIVA Foundation to Enhance TB Diagnosis through Whole Genome Sequencing
    • 13.3.3. VinBrain Partners with Vietnam's National TB Screening Initiative to Combat Tuberculosis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Becton, Dickinson, and Company
  • 3. Bio-Rad Laboratories, Inc.
  • 4. bioMerieux SA
  • 5. Bruker Corporation
  • 6. Cepheid by Danaher Corporation
  • 7. Elisabeth Pharmacon, spol. s r.o.
  • 8. ELITech Group SAS
  • 9. F. Hoffmann-La Roche AG
  • 10. Fujifilm Holdings Corporation
  • 11. Hologic Corporation
  • 12. Lionex Diagnostics & Therapeutics GmbH
  • 13. OSANG HEALTHCARE CO., LTD
  • 14. PerkinElmer, Inc.
  • 15. SD Biosensor, INC.
  • 16. Siemens AG
  • 17. Thermo Fisher Scientific, Inc.
  • 18. Trivitron Healthcare Private Limited
  • 19. Tulip Diagnostics (P) Ltd
  • 20. Turklab A.S.

LIST OF FIGURES

  • FIGURE 1. TUBERCULOSIS TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. TUBERCULOSIS TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. TUBERCULOSIS TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. TUBERCULOSIS TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. TUBERCULOSIS TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. TUBERCULOSIS TESTING MARKET DYNAMICS
  • TABLE 7. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE-BASED TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY INTERFERON-GAMMA RELEASE ASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY MANTOUX TUBERCULIN SKIN TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SMEAR MICROSCOPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ACTIVE TB INFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LATENT TB INFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY IN-LABORATORY TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY POINT-OF-CARE TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY GOVERNMENT & PUBLIC HEALTH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 192. TUBERCULOSIS TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 193. TUBERCULOSIS TESTING MARKET, FPNV POSITIONING MATRIX, 2023